Clinical trial
PULSAR - A Prospective Study to Evaluate the Utility of Low Doses of the Statins…
NCT00329173 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00329173 |
|---|---|
| Title | PULSAR - A Prospective Study to Evaluate the Utility of Low Doses of the Statins Atorvastatin and Rosuvastatin. |
| Official title | A 6-Week Open-Label, Randomised, Multicentre, Phase IIIb, Parallel-Group Study to Compare the Efficacy and Safety of Rosuvastatin (10 mg) With Atorvastatin (20 mg) in Subjects With Hypercholesterolaemia and Either a History of CHD or Clinical Evidence of CHD |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Hypercholesterolaemia |
| Intervention type | Drug |
| Interventions | Rosuvastatin, Atorvastatin |
| Enrollment | 1,000 |
| Start date | Nov 1, 2003 |
| Completion | Aug 1, 2004 |
| First posted | May 24, 2006 |
| Last update posted | Mar 16, 2009 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: